In an open-label, dose-escalation phase I study, 27 patients with advanced melanoma (who had progressed on or during at least 1 prior therapy) received intravenous IMC-20D7S (a recombinant human IgG1 monoclonal antibody targeting TYRP1) every 2 or 3 weeks. Here, TYRP1 is linked to melanoma.